Related Experiment Video

Updated: May 16, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis

Christian Beyer1, Clara Dees1, Jörg H W Distler2

  • 1Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Ulmenweg 18, 91054, Erlangen, Germany.

Archives of Dermatological Research
|December 5, 2012
PubMed

Insights

Wnt, Hedgehog, and Notch signaling pathways drive fibrosis in systemic sclerosis. Inhibiting these pathways shows promise for treating fibrotic diseases like SSc.

Area of Science:

  • Molecular Biology
  • Pathogenesis of Fibrotic Diseases

Background:

  • Morphogen pathways, including Wnt, Hedgehog, and Notch, are vital for development and tissue maintenance.
  • Dysregulation of these pathways contributes to various diseases, notably fibrotic conditions.

Purpose of the Study:

  • To review the pro-fibrotic roles of Wnt, Hedgehog, and Notch signaling in systemic sclerosis (SSc).
  • To explore the therapeutic potential of inhibiting these pathways for fibrosis treatment.

Main Methods:

  • Review of existing literature on Wnt, Hedgehog, and Notch signaling in SSc pathogenesis.
  • Analysis of preclinical models demonstrating the effects of pathway inhibition on fibrosis.

Main Results:

  • Wnt, Hedgehog, and Notch pathways are activated in SSc, promoting fibroblast differentiation into myofibroblasts.
  • These activated pathways stimulate the release of collagen and extracellular matrix components.
  • Inhibition of these morphogen pathways effectively prevents and reverses experimental fibrosis.

Conclusions:

  • Wnt, Hedgehog, and Notch signaling are key drivers of fibrosis in SSc.
  • Targeting these pathways represents a promising novel therapeutic strategy for fibrotic diseases.
  • Clinical trials are underway for inhibitors of these pathways, suggesting potential for treating fibrosis.

More Related Videos

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies06:46

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies

Published on: February 15, 2019

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...